Novavax, Inc. (NVAX) Baird 2024 Global Healthcare Conference (Transcript) Novavax in $123.8M settlement with U.K. agency over ...

Novavax said the Food and Drug Administration has put a hold on its application for a combination shot targeting Covid and ...

announced that the U.S. FDA has removed the clinical hold on Novavax’s Investigational New Drug application for its COVID-19-Influenza Combination and stand-alone influenza vaccine candidates.

The lifted hold applies to Novavax’s flu ... combo vaccine. A trial participant who’d received the shot in Jan. 2023 later developed motor neuropathy, or muscle weakness, leading the FDA ...

After evaluating the data, the FDA concluded that the ALS diagnosis was unrelated to Novavax’s vaccine. With the regulatory hold lifted ... by standard flu and Covid-19 vaccines.

has removed the clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. The FDA has cleared ...

the FDA removed the clinical hold on Novavax Inc.’s (NASDAQ:NVAX) Investigational New Drug (IND) application for its COVID-19-influenza combination (CIC) and stand-alone influenza vaccine ...

(Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on Novavax ...

Novavax NVAX announced that it has started dosing participants in the phase III study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.

Sanofi SNY announced that the FDA has granted ... and Flublok flu vaccines. Novavax recently signed a multi-billion dollar deal with Sanofi for its protein-based COVID-19 vaccine.